
    
      Patients will be treated either with oral GNS561 plus standard of care or only standard of
      care. All patients in experimental arm will be treated for ten days. Study drug will be
      provided as oral capsules containing 200 mg of GNS561. Patients will be followed-up during
      hospitalization and after discharge.
    
  